Cargando…

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma

PURPOSE: Tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor receptor (VEGFR) signaling pathways have been used for metastatic clear cell renal cell carcinoma (mCCRCC), but resistance to the drug develops in most patients. We aimed to explore the underlying mechanism of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Se Un, Hwang, Hee Sang, Park, Ja-Min, Yoon, Sun Young, Shin, Su-Jin, Go, Heounjeong, Lee, Jae-Lyun, Jeong, Gowun, Cho, Yong Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873321/ https://www.ncbi.nlm.nih.gov/pubmed/35240013 http://dx.doi.org/10.4143/crt.2021.1526

Ejemplares similares

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma
por: Hwang, Hee Sang, et al.
Publicado: (2020)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors
por: Jeong, Se Un, et al.
Publicado: (2017)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

mTOR-Related Cell-Clearing Systems in Epileptic Seizures, an Update
por: Limanaqi, Fiona, et al.
Publicado: (2020)

Synaptophysin, CD117, and GATA3 as a Diagnostic Immunohistochemical Panel for Small Cell Neuroendocrine Carcinoma of the Urinary Tract
por: Kim, Gi Hwan, et al.
Publicado: (2022)

Relationship Status Update on Astrocytic VEGFR-3 and mTOR Signaling: It’s Complicated
por: Brewster, Amy L.
Publicado: (2021)

Analysis of mTOR Inhibition-Involved Pathway in Ovarian Clear Cell Adenocarcinoma
por: Harasawa, Makiko, et al.
Publicado: (2011)

mTOR Modulates Methamphetamine-Induced Toxicity through Cell Clearing Systems
por: Lazzeri, Gloria, et al.
Publicado: (2018)

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
por: Chen, Chun-Hau, et al.
Publicado: (2019)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma
por: An, Hyo Jung, et al.
Publicado: (2019)

Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma
por: Li, Na, et al.
Publicado: (2021)

Morphology, clearing efficacy, and mTOR dependency of the organelle autophagoproteasome
por: Limanaqi, Fiona, et al.
Publicado: (2021)

Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
por: Ji, Lijun, et al.
Publicado: (2018)

Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023)

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Ginsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling–mediated muscular hypertrophy and myoblast differentiation
por: Go, Ga-Yeon, et al.
Publicado: (2020)

mTOR-sensitive translation: Cleared fog reveals more trees
por: Masvidal, Laia, et al.
Publicado: (2017)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway
por: Yamazaki, Shota, et al.
Publicado: (2018)

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
por: Park, Inkeun, et al.
Publicado: (2019)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

DUSP9 Suppresses Proliferation and Migration of Clear Cell Renal Cell Carcinoma via the mTOR Pathway
por: Luo, Jing, et al.
Publicado: (2020)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

Nanotechnology-Based Targeting of mTOR Signaling in Cancer
por: Yoon, Mee-Sup
Publicado: (2020)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
por: Hu, Yi, et al.
Publicado: (2020)

mTOR sends T cells on their way
por: LeBrasseur, Nicole
Publicado: (2008)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma
por: Kim, Jisup, et al.
Publicado: (2021)

Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
por: Deng, Xiaobing, et al.
Publicado: (2014)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma
por: Fan, Demin, et al.
Publicado: (2020)

Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma
por: Long, Shichao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kit3tj1dv54shp4s1jdtp281qd